Yoshihide Tomata

This inventor holds 15 USPTO granted patents and 2 published patent applications and 4 EPO patents, primarily in Heterocyclic Compounds. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2014-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yoshihide Tomata. Retrieved from https://idiyas.com/inventor/yoshihide-tomata

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 15 (Patent Applications = 2)

% Patents Active = 26.7

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 11.5

ph-index = 3

Forward Citations = 20(Granted Patents)

Location History:

Fujisawa, JP (2017)
San Diego, CA (US) (2018 - 2023)
Kanagawa, JP (2014 - 2024)

Company Filing History:

15 out of 1,232

Takeda Pharmaceutical Company Limited

patents

Years Active: 2014-2024

Loading Chart...

Areas of Expertise:

Heterocyclic Compounds

Amide Compounds

ROR Gamma-T Inhibitors

RORvt Inhibitory Action

RORyT Inhibitory Action

Condensed Heterocyclic Compounds

Pharmaceutical Applications

Chemical Synthesis

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12077522 - Heterocyclic compound and application thereof (2024-09-03),

2. 11851449 - Heterocyclic amide compounds having an RORvt inhibitory action (2023-12-26),

3. 11053262 - Heterocyclic amide compounds having RORyT inhibitory action (2021-07-06),

4. 10472376 - Amide compound (2019-11-12),

5. 10093629 - Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors (2018-10-09),

6. 10053468 - Heterocyclic compound (2018-08-21),

7. 10000488 - Heterocyclic compound (2018-06-19),

8. 9834520 - Heterocyclic compound (2017-12-05),

9. 9650343 - Heterocyclic compound (2017-05-16),

10. 9630924 - Heterocyclic compound (2017-04-25),

11. 9573903 - Heterocyclic compound (2017-02-21),

12. 9365520 - Heterocyclic compound (2016-06-14),

13. 9156837 - Heterocyclic compound (2015-10-13),

14. 9120776 - Condensed heterocyclic compound (2015-09-01),

15. 8822699 - Heterocyclic compound and use thereof (2014-09-02),

Title: Innovations by Yoshihide Tomata: Advancements in Heterocyclic Compounds

Introduction: Yoshihide Tomata, an accomplished inventor based in Kanagawa, Japan, has made significant contributions to the field of pharmaceuticals, specifically focusing on heterocyclic compounds. With a portfolio of 15 patents, Tomata's work is influential in the ongoing research aimed at treating various medical conditions.

Latest Patents: Among his notable inventions, Tomata has developed groundbreaking patents including a heterocyclic compound that acts as an orexin type 2 receptor agonist. This invention is particularly valuable for its potential use in the prophylaxis and treatment of narcolepsy. Additionally, he has patented heterocyclic amide compounds that exhibit RORγt inhibitory action, which could play a crucial role in various therapeutic applications.

Career Highlights: Tomata is affiliated with Takeda Pharmaceutical Company Limited, a prominent player in the pharmaceutical industry. His dedication to innovation and research aligns with Takeda's mission to develop advanced treatments and improve patient outcomes. His work exemplifies the intersection of scientific inquiry and practical application in medicine.

Collaborations: Throughout his career, Tomata has collaborated with esteemed colleagues such as Satoshi Yamamoto and Junya Shirai. These collaborations enhance the innovative potential of his research, fostering a creative environment for tackling complex medical challenges.

Conclusion: Yoshihide Tomata's contributions to the field of pharmacology highlight the importance of innovation in developing novel treatments. His patents not only reflect a commitment to scientific advancement but also promise to improve the quality of life for individuals suffering from conditions like narcolepsy. Tomata's work is a testament to the vital role of inventors in shaping the future of healthcare.

Profile summary based on public USPTO records.